TOP STORY

PU.1-Mediated Upregulation of CSF1R is Crucial for Leukemia Stem Cell Potential Induced by MOZ-TIF2
Using an acute myeloid leukemia (AML) model induced by the leukemia-associated monocytic leukemia zinc finger (MOZ)-TIF2 fusion protein, researchers show here that AML can be cured by the ablation of leukemia stem cells. [Nat Med]

HEMA  
Become an expert at colony identification
Hematopoietic Progenitor Assay Training Course
by STEMCELL Technologies
 
 
REGISTER HERE STEMCELL Technologies Inc
 



SPECIAL FEATURE

Complimentary Webinar Presented by STEMCELL Technologies

Instructing Lineage Choice: Assays to Determine Effects of Cytokines and Novel Compounds on Hematopoiesis

Thursday, May 13, 2010 at 9:00 a.m. EDT; 2:00 p.m. BST
Ideal for participants in Europe

Thursday, May 13, 2010 at 9:00 a.m. PDT
Ideal for participants in North America

More Information



SCIENCE NEWS

Tackling Blood Stem Cell Heterogeneity
Distinct populations of hematopoietic stem cells that preferentially generate specific types of blood cells can be identified based on abundance of a single surface protein, according to a study. [Press release from EurekAlert! discussing online prepublication in Journal of Experimental Medicine]

MethoCult®  
MethoCult®
The most published medium for hematopoietic CFC assays

by STEMCELL Technologies
 
 
TEST YOUR COLONY IDENTIFICATION SKILLS STEMCELL Technologies Inc
 



CURRENT PUBLICATIONS

LABORATORY RESEARCH

Heterogeneity and Hierarchy Within the Most Primitive Hematopoietic Stem Cell Compartment
Researchers attempted prospective isolation of hematopoietic stem cell subsets with distinct properties among CD34-/low c-Kit+Sca-1+Lin- [CD34(-)KSL] cells. [J Exp Med]

Tel1/ETV6 Specifies Blood Stem Cells through the Agency of VEGF Signaling
Researchers show that the leukemia-associated Ets transcription factor, Tel1/ETV6, specifies the first hematopoietic stem cells in the dorsal aorta. [Dev Cell]

Hematopoietic and Non-Hematopoietic Cell Tissue Factor Activates the Coagulation Cascade in Endotoxemic Mice
In this study, researchers investigated the effect of either a selective inhibition of tissue factor (TF) expression or cell type-specific deletion of the TF gene on activation of coagulation in a mouse model of endotoxemia. [Blood]

Rac2 GTPase Deficiency Depletes BCR-ABL+ Leukemic Stem Cells and Progenitors In Vivo
Rac2-deficiency exhausts the leukemic stem cell pool in vivo through impairment of oncogene-induced proliferation and survival signals. [Blood]

Senescence Induction in Human Fibroblasts and Hematopoietic Progenitors by Leukemogenic Fusion-Proteins
Here researchers show that three leukemogenic fusion-proteins, BCR-ABL, CBFB-MYH11 and RUNX1-ETO, can induce senescence in primary fibroblasts and hematopoietic progenitors. [Blood]

Knockdown of SOD1 Sensitizes the CD34+ CML Cells to Imatinib Therapy
In this study, researchers found that the CD34+ subpopulation in the chronic myelogenous leukemia (CML) cell line K562 had a higher expression of SOD1 than that in the CD34 negative cells. [Med Oncol]

CLINICAL RESEARCH

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
Researchers report the impact of organic cation transporter-1 (OCT-1) activity on loss of response, disease transformation, and survival after 5 years of imatinib. [J Clin Oncol]

Prognostic Effect of Chromosomal Abnormalities in Childhood B Cell Precursor Acute Lymphoblastic Leukemia: Results from the UK Medical Research Council ALL97/99 Randomised Trial
Researchers analysed cytogenetic data from 1725 children with B cell precursor acute lymphoblastic leukemia who were included in the UK Medical Research Council ALL97/99 study and followed up for a median time of 8.2 years. [Lancet Oncol]

Autologous Purified Peripheral Blood SCT in Childhood Low-Risk Relapsed ALL
The aim of this report is to assess the long-term outcome of children with 'low-risk' relapsed acute lymphoblastic leukemia (ALL) treated according to a prospective purified auto-transplantation protocol. [Bone Marrow Transplant]


INDUSTRY NEWS

Dyax Corp. Sells Rights to Xyntha(R) Royalty Stream to Paul Capital Healthcare for Up To $12 Million
Dyax Corp. announced that it has sold its rights to royalties and other payments related to the commercialization of Xyntha(R) by Pfizer, Inc., a licensee under the Company's phage display Licensing and Funded Research Program, to an investment fund managed by Paul Capital Healthcare. [Dyax Corp. Press Release]

Hemaquest Raises $12 Million in Venture Backing
Drug developer Hemaquest Pharmaceuticals Inc. has raised $12 million in venture capital. The round was led by Aberdare Ventures and included existing investors De Novo Ventures, Forward Ventures and Lilly Ventures. [Boston Business Journal]

Amgen Beats but Tones Down Outlook
Amgen reported first quarter earnings per share of $1.28, 5 cents above the Zacks Consensus Estimate of $1.23 and well above the year-ago earnings of $1.07. [Yahoo! Finance]


POLICY NEWS

Native American Research Lawsuit Settled
Two lawsuits brought by the Native American tribal government and its members against Arizona State University were settled for $700,000, closing the books on the remaining legal points after six years of courtroom battles. [Nature: The Great Beyond]

Michigan Senate Passes Stem Cell Regulation Package
The Republican-led Senate passed a package of regulations critics say will place a chill on stem cell research in violation of the Michigan Constitution. [Michigan Senate, United States]

Gubernatorial Candidates Talk Ways to Boost Bioscience
Five gubernatorial candidates offered their prescriptions for creating a healthier climate for Minnesota's biotech industry that included lower taxes, higher government spending, and faith in science over ideology. [Minnesota, United States]

Request for Information (RFI): Priorities for the NIH Adherence Research Network (NOT-OD-10-078) [National Institutes of Health, United States]

Waivers for Conflicts of Interest for the May 7, 2010 Vaccines and Related Biological Products Advisory Committee Meeting [Food and Drug Administration, United States]

FDA Announces Draft Revised Guidance on Transparency and Advisory Committees [Food and Drug Administration, United States]

Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and Food and Drug Administration Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers; Availability (Docket No. FDA-2002-D-0094) [Food and Drug Administration, United States]


EVENTS

European Symposium on Stem Cell Research for Stroke
May 4-5, 2010
Lille, France

Stem Cells, Tissue Homeostasis and Cancer Conference
May 12-15, 2010
Heidelberg, Germany

16th International Society for Cellular Therapy (ISCT) Meeting
May 23-26, 2010
Philadelphia, United States

Systems Biology of Stem Cells
May 24-25, 2010
Irvine, United States

International Symposium, Stem Cells in Biology and Disease
May 26-28, 2010
Lisbon, Portugal

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI)
June 26-July 1, 2010
Berlin, Germany

The European Molecular Biology Organization (EMBO) Meeting 2010
September 4-7, 2010
Barcelona, Spain

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

Stem Cells and Regeneration
October 3-9, 2010
Woods Hole, United States

American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States

Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.




JOB OPPORTUNITIES

Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization's career opportunities with Cell Therapy News.
Visit here to post your career opportunities.


Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

forwardafriendicon